INM Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-10-27 | 2022 | Alexandra Mancini Senior Vice President, Clinical & Regulatory Affairs | 261,027 | 0 | 0 | 0 | 0 | 290,483 |
| 2023-10-27 | 2023 | Alexandra Mancini Senior Vice President, Clinical & Regulatory Affairs | 237,778 | 41,611 | 0 | 0 | 0 | 284,920 |
| 2023-10-27 | 2022 | Michael Woudenberg Chief Operating Officer | 302,250 | 0 | 0 | 0 | 0 | 330,197 |
| 2023-10-27 | 2023 | Michael Woudenberg Chief Operating Officer | 239,619 | 47,924 | 0 | 0 | 0 | 297,421 |
| 2023-10-27 | 2022 | Eric A. Adams President, Chief Executive Officer and Director | 363,168 | 0 | 0 | 0 | 0 | 468,368 |
| 2023-10-27 | 2023 | Eric A. Adams President, Chief Executive Officer and Director | 278,253 | 69,563 | 0 | 0 | 0 | 367,571 |
| 2022-10-28 | 2022 | Bruce Colwill Former Chief Financial Officer | 244,683 | 0 | 0 | 0 | 0 | 295,179 |
| 2022-10-28 | 2021 | Bruce Colwill Former Chief Financial Officer | 273,597 | 123,941 | 0 | 0 | 0 | 515,966 |
| 2022-10-28 | 2022 | Eric A. Adams President, Chief Executive Officer and Director | 363,168 | 0 | 0 | 0 | 0 | 468,368 |
| 2022-10-28 | 2021 | Eric A. Adams President, Chief Executive Officer and Director | 327,809 | 160,627 | 0 | 0 | 0 | 735,161 |
| 2022-10-28 | 2022 | Alexandra Mancini Senior Vice President, Clinical & Regulatory Affairs | 261,027 | 0 | 0 | 0 | 0 | 290,483 |
| 2022-10-28 | 2021 | Alexandra Mancini Senior Vice President, Clinical & Regulatory Affairs | 252,346 | 84,788 | 0 | 0 | 0 | 406,217 |
| 2022-10-28 | 2022 | Eric Hsu Senior Vice President, PreClinical R&D | 253,461 | 0 | 0 | 0 | 0 | 282,917 |
| 2022-10-28 | 2021 | Eric Hsu Senior Vice President, PreClinical R&D | 244,327 | 84,659 | 0 | 0 | 0 | 398,069 |
| 2021-10-28 | 2020 | Alexandra Mancini Senior VP, Clinical & Regulatory Affairs | 230,133 | 78,058 | 0 | 0 | 0 | 308,191 |
| 2021-10-28 | 2021 | Alexandra Mancini Senior VP, Clinical & Regulatory Affairs | 252,346 | 84,788 | 0 | 0 | 0 | 406,217 |
| 2021-10-28 | 2020 | Bruce Colwill 2 CFO & Secretary | 202,762 | 85,830 | 0 | 0 | 0 | 429,353 |
| 2021-10-28 | 2021 | Bruce Colwill 2 CFO & Secretary | 273,597 | 123,941 | 0 | 0 | 0 | 515,966 |
| 2021-10-28 | 2020 | Eric A. Adams President and CEO Director | 287,257 | 136,500 | 0 | 0 | 0 | 423,757 |
| 2021-10-28 | 2021 | Eric A. Adams President and CEO Director | 327,809 | 160,627 | 0 | 0 | 0 | 735,161 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
